Business
Cryoport and Cell and Gene Therapy Catapult Announce Strategic Collaboration at Stevenage Manufacturing Innovation Centre for Advancement of Cell and Gene Therapies
Partnership Establishes Cryoport Systems' First U.K. Logistics Center to Support Future Expansion and Provide End-to-End Supply Chain Solutions for Advanced
About this update from Cryoport, Inc.
[{"type":"text","content":"Partnership Establishes Cryoport Systems' First U.K. Logistics Center to Support Future Expansion and Provide End-to-End Supply Chain Solutions for Advanced Therapy Manufacturers\nNASHVILLE, Tenn. and STEVENAGE, United Kingdom, Oct. 10, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (\"Cryoport\"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, and the Cell and Gene Therapy Catapult (\"CGT Catapult\"), an independent innovation and technology organisation specializing in the advancement of cell and gene therapies, today announced the organisations have entered into a new strategic partnership to support the advancement of cell and gene therapies.\n\n \n \n \n \n \n \n\n \nThrough this collaboration, Cryoport Systems will establish its first global supply chain logistics centre in the U.K., a Good Manufacturing Practice (GMP)-compliant facility located within the bioscience cluster in Stevenage, U.K., at the CGT Catapult's large-scale cell and gene therapy Stevenage Manufacturing Innovation Centre. The partnership will provide CGT Catapult collaborators, and the larger U.K. cell and gene therapy community, with access to Cryoport's integrated, end-to-end supply chain capabilities including risk mitigation services and logistics support. The collaboration between the partners will commence operations in early 2024.\n\"The cell and gene therapy industry has become an area of rapid growth in the U.K. with increasing governmental support, making now the prime opportunity to partner with CGT Catapult to offer advanced therapy manufacturers streamlined solutions for their cold chain logistics needs,\" said Jerrell Shelton, CEO of Cryoport. \"This partnership provides a valuable step in the expansion of our global supply chain infrastructure buildout to help accelerate the process of clinical development and commercialization of cell and gene therapies in the U.K. It also expands Cryoport Systems' footprint and advances our longer-term plans in this region by starting with this initial foothold.\"\nMatthew Durdy, Chief Executive of the Cell and Gene Therapy Catapult, added, \"Cryoport's expertise in the logistics and supply chain needs of advanced therapy manufacturers is an invaluable addition to the lif...